Tenofovir (all routes except local)

Maternal consequences (as a whole)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5293
R13654
Zeng (Controls exposed to telbivudine), 2019 Adverse pregnancy 2nd and/or 3rd trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No Control group: telbivudine Exposed group: TDF (only) Indication: CHB 1.04 [0.30;3.54] C
excluded (control group)
5/71   6/88 11 71
ref
S5712
R14210
Zeng (Controls unexposed, sick), 2019 Adverse pregnancy 2nd and/or 3rd trimester prospective cohort unexposed, sick Adjustment: No Control group: Unexposed, sick Exposed group: TDF (only) Indication: CHB 1.09 [0.25;4.78] C 5/71   3/46 8 71
ref
S5304
R13748
Jourdain a, 2018 Maternal adverse event of grade 3 or 4 or serious adverse event 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Control group: Unexposed, sick Exposed group: TDF (only) Indication: CHB 0.87 [0.53;1.43] C 41/168   44/163 85 168
ref
Total 2 studies 0.89 [0.56;1.43] 93 239
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Zeng (Controls unexposed, sick), 2019Zeng, 2019 1 1.09[0.25; 4.78]87110%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Jourdain a, 2018Jourdain a, 2018 0.87[0.53; 1.43]8516890%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 0.89[0.56; 1.43]932390.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.89[0.56; 1.43]932390%NAZeng (Controls unexposed, sick), 2019 Jourdain a, 2018 2 case control studiescase control studies 0 RCTRCT 0.87[0.53; 1.43]85168 -NAJourdain a, 2018 1 Type of controls unexposed, sickunexposed, sick 0.89[0.56; 1.43]932390%NAZeng (Controls unexposed, sick), 2019 Jourdain a, 2018 2 Tags Adjustment   - No  - No 1.09[0.25; 4.78]871 -NAZeng (Controls unexposed, sick), 2019 1   - Randomisation  - Randomisation 0.87[0.53; 1.43]85168 -NAJourdain a, 2018 1 Control group   - Unexposed, sick  - Unexposed, sick 0.89[0.56; 1.43]932390%NAZeng (Controls unexposed, sick), 2019 Jourdain a, 2018 2 Exposed group   - TDF (only)  - TDF (only) 0.89[0.56; 1.43]932390%NAZeng (Controls unexposed, sick), 2019 Jourdain a, 2018 2 Indication   - CHB  - CHB 0.89[0.56; 1.43]932390%NAZeng (Controls unexposed, sick), 2019 Jourdain a, 2018 2 All studiesAll studies 0.89[0.56; 1.43]932390%NAZeng (Controls unexposed, sick), 2019 Jourdain a, 2018 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 5293

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.89[0.56; 1.43]932390%NAZeng (Controls unexposed, sick), 2019 Jourdain a, 2018 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.04[0.30; 3.54]1171 -NAZeng (Controls exposed to telbivudine), 2019 10.510.01.0